New drug combo aims to shrink ovarian tumors in 30-Patient trial
NCT ID NCT07339553
First seen Jan 21, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether combining two drugs, zeprumetostat and fuzuloparib, can shrink tumors in people with advanced or recurrent ovarian cancer. About 30 adults aged 18-75 with a specific genetic profile (BRCA1/2 wild-type) will take part. The main goal is to see how many patients have their tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIANCANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.